HeartSciences Inc. (HSCSW)

HeartSciences makes software that reads electrocardiograms—the electrical squiggles that hospitals and clinics print out when they attach electrodes to your chest. The company uses machine learning to spot patterns in those electrical signals that might indicate heart disease. The goal is to catch problems early, before they turn into heart attacks.

The basic idea

Every time your heart beats, it fires electrical signals. An EKG machine records those signals on a strip of paper or a screen. Doctors have trained for years to look at the wiggly lines and see signs of trouble. But humans get tired. They miss things. They read the same patterns differently on different days.

HeartSciences built software that does this work automatically. Feed it an EKG from a patient, and the software spits out a score. The score tells you whether the EKG shows signs of hidden coronary artery disease—the kind of disease that hasn’t caused a heart attack yet but could. The software is trying to find the problem while there’s still time to fix it with a stent or medication, rather than waiting until the person collapses with a heart attack.

How it works

Coronary artery disease happens when plaque builds up inside the arteries that feed your heart muscle. You might have no symptoms until the artery gets so narrow that not enough blood reaches the heart. That’s when you have chest pain or a heart attack. Catching it early means finding the disease before it pinches off blood flow.

The software analyzes the electrical patterns the heart makes as it beats. A healthy heart makes one pattern. A heart with blocked arteries makes different patterns—subtle ones that a harried nurse or ER doctor might not catch. The AI has been trained on thousands of EKGs from patients who also had heart catheterization (the gold standard test that actually lets you see inside the arteries) or stress tests (which provoke the heart to see if it’s getting enough blood). So the software learned what the bad ones look like.

When a new patient comes in and gets an EKG, the software analyzes the recording. If it finds patterns that match the ones it learned from sick patients, it flags the case. The doctor then knows to think harder about that patient’s heart risk and might order more tests.

What HeartSciences is actually selling

The company does not sell the software directly to patients. It sells to hospitals, clinics, and diagnostic centers that already own EKG machines. The pitch is simple: feed your EKG readings into our software, and it will give you an extra layer of screening for hidden heart disease. Some customers pay a subscription fee per month. Others pay per test. The economics are not fully transparent because the company is not large and does not disclose detailed revenue numbers, but the model is asset-light—once the software is built, adding more customers costs very little.

The real customer is not even the hospital; it is the patient. The software has to perform well enough that doctors trust it and order follow-up tests when it flags something. It also has to be easy enough to use that busy clinics will adopt it and use it consistently. Many medical devices fail not because they don’t work but because they are too cumbersome to integrate into a hospital’s workflow.

Regulatory pathway and challenges

To sell this software in the United States, HeartSciences needs FDA clearance or approval. The FDA regulates medical devices, especially those that diagnose disease or guide treatment. Getting through that process is expensive, slow, and uncertain. The company has sought clearance multiple times and faced setbacks. Every regulatory rejection means more development work, more money spent, and more uncertainty about whether the product will ever reach the market.

Beyond the FDA, doctors need to believe the software is accurate. Academic papers help. Real-world studies help more. HeartSciences has published research showing its software can detect coronary disease, but the medical community moves slowly. A new diagnostic tool has to prove itself again and again before it becomes standard practice.

Another layer is reimbursement. Even if the FDA clears the software and doctors trust it, it matters whether health insurance plans will pay for it. If insurers don’t cover it, few patients will use it and few clinics will buy it. Reimbursement decisions are made by big insurance companies and government programs like Medicare. Those decisions lag behind FDA approval by years.

The competition and the market

HeartSciences is not alone. Larger medical-device companies like Philips, GE, and Siemens all have EKG machines and some have added AI algorithms to them. Specialized startups are also building AI-powered diagnostic software. The advantage of being small is speed and focus. The disadvantage is capital and reach—big companies have R&D budgets, sales forces, and existing relationships with hospitals that startups lack.

The overall market for AI-powered diagnostic devices is growing. Healthcare systems are under pressure to do more with less. A tool that spots disease earlier or catches diagnoses that would have been missed is valuable. But adoption is not automatic. Doctors are conservative. Hospital IT systems are complicated. And there are always questions about who pays for the software and the follow-up tests.

What we don’t know

HeartSciences is a micro-cap company, not a large one. It is not as transparent as big public companies. Exact revenue figures, profit margins, customer counts—these are not widely disclosed. That makes it hard to assess whether the business is actually working or just raising money on the promise of AI and healthcare. Some medical-device startups are genuinely improving patient care. Others are overpromising and underdelivering.

The company’s stock trades on the OTCQB, a smaller exchange for smaller companies, which is a sign that it is still early-stage. Many investors avoid OTC stocks because of lower liquidity and less regulation.

How to follow the company

If you are interested in HeartSciences, the 10-K filing is the starting point (SEC CIK 0001468492), although it may not have as much detail as a large-cap filing. Look for any regulatory approvals or rejections, customer wins, clinical publications, and reimbursement news. Watch the cash position—early-stage medical-device companies burn cash while developing and pursuing regulatory approval. If the company runs out of money before a breakthrough, the stock goes to zero. Track any partnerships with larger healthcare companies, which might mean validation or distribution help. Finally, follow press releases for clinical trial results or FDA decisions, as those are the key catalysts that move the stock.